50. Dermatomyositis Clinical trials / Disease details

Clinical trials : 194 / Drugs : 244 - (DrugBank : 89) / Drug target genes : 50 - Drug target pathways : 151

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCTs031200005	30/04/2020	10/04/2020	Investigation on the safety and utility of apremilast for the treatment of refractory rash in patients with dermatomyositis	Investigation on the safety and utility of apremilast for the treatment of refractory rash in patients with dermatomyositis - ACDM	Dermatomyositis Collagen disease, inflammatory myopathy, cutaneous manifestation;D003882	Oral administration of apremilast: Start with 10 mg of oral dose and gradually increase the dose until day 5, 30mg twice a day from day 6 (morning / evening) for a total of 12 weeks	Okiyama Naoko	NULL	Complete	>= 20age old	< 80age old	Both	5	Phase 1-2	Japan
2	NCT03529955 (ClinicalTrials.gov)	June 12, 2018	24/4/2018	Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis	A Phase 2, Open Label Single Arm Study for Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis	Dermatomyositis, Adult Type	Drug: Apremilast 30mg	Tulane University	NULL	Completed	18 Years	75 Years	All	10	Phase 2	United States
3	NCT01140503 (ClinicalTrials.gov)	February 2010	6/4/2010	A Study to Evaluate the Safety and Efficacy of Apremilast in the Treatment of Skin Disease in Patients With Dermatomyositis	An Open Label Study Evaluating the Safety and Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Dermatomyositis	Dermatomyositis	Drug: Apremilast	Stanford University	NULL	Terminated	18 Years	N/A	All	5	N/A	United States